Cindy Whitehead, the CEO of Sprout Pharmaceuticals who oversaw the first prescription drug to enhance women’s sexual drive, is quitting just two months after the company was bought by Valeant. According to a statement from Valeant, she will, however, continue to consult with Valeant and Sprout executives after her departure. Sprout Pharmaceuticals – Whitehead successfully shepherded Addyi’s launch Citing concerns about side effects and limited effectiveness, the Food and Drug Administration rejected in 2010 and in 2013 Sprout’s Addyi, often referred to as the “little pink pill.” After the FDA initially rejected Addyi, the pharmaceutical company Boehringer Ingelheim dropped it. However, Ms. Whitehead…
Sprout Pharmaceuticals CEO Cindy Whitehead Resigns
Mani
Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports